Addex to Present at the BIO CEO & Investor Conference
10.02.2012 07:32:05 -
(live-PR.com) -
GENEVA -- (Marketwire) -- 02/10/12 --
Addex Pharmaceuticals (SWISS: ADXN), a
leading biopharmaceutical company pioneering allosteric modulation-based
drug
discovery and development, announced today that Dr. Bharatt Chowrira,
CEO of
Addex, will present at 9am EST on February 14, 2012, at the BIO CEO &
Investor
Conference in New York City. Dr. Chowrira will highlight the Company's
oral
small molecule drug discovery and development platform and provide a
review of
its pipeline,
including two lead products in Phase IIa testing for
Parkinson's
disease and schizophrenia. The presentation, live webcast and webcast
replay
will be available via the Internet at:
www.veracast.com/webcasts/bio/ceoinvestor2012/08 .. : www.veracast.com/webcasts/bio/ceoinvestor2012/08 ..
Addex Pharmaceuticals ( www.addexpharma.com : www.addexpharma.com ) discovers and develops an
emerging
class of small molecule drugs, called allosteric modulators, which
have the
potential to be more specific and confer significant therapeutic advantages
over
conventional "orthosteric" small molecule or biological drugs. The Company
uses
its proprietary discovery platform to address receptors and other proteins
that
are recognized as attractive targets for modulation of important diseases
with
unmet medical needs. The Company's two lead products are being
investigated in
Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5
negative
allosteric modulator or NAM) is being developed by Addex to treat
Parkinson's
disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2
positive
allosteric modulator or PAM) is being developed by our partner
Janssen
Pharmaceuticals Inc. to treat schizophrenia. Addex also is advancing
several
preclinical programs including: GABA-BR PAM for pain, overactive
bladder and
other disorders; mGluR4 PAM for Parkinson's, anxiety and other diseases;
GLP1R
PAM for type 2 diabetes; mGluR2 NAM for treating Alzheimer's
disease and
depression; and FSHR/LHR NAM for sex hormone dependent tumors &
reproductive
system disorders. In addition, Addex has discovery programs to
identify
allosteric modulators of: receptor tyrosine kinase (RTK) superfamily,
including
TrkB PAM for treating neurodegenerative diseases (e.g. Alzheimer's,
Parkinson's
and Huntington's diseases); and TNF receptor superfamily, including
TNFR1 NAM
for inflammation (e.g. rheumatoid arthritis) and other diseases.
Disclaimer: The foregoing release may contain forward-looking statements
that
can be identified by terminology such as "not approvable",
"continue",
"believes", "believe", "will", "remained open to exploring", "would",
"could",
or similar expressions, or by express or implied discussions regarding
Addex
Pharmaceuticals Ltd, its business, the potential approval of its
products by
regulatory authorities, or regarding potential future revenues from
such
products. Such forward-looking statements reflect the current views of
Addex
Pharmaceuticals Ltd regarding future events, future economic
performance or
prospects, and, by their very nature, involve inherent risks and
uncertainties,
both general and specific, whether known or unknown, and/or any other
factor
that may materially differ from the plans, objectives, expectations,
estimates
and intentions expressed or implied in such forward-looking statements.
Such may
in particular cause actual results with allosteric modulators of mGluR2,
mGluR4,
mGluR5, mGluR7, GABA-BR, FSHR/LHR, GLP1R, TNFR1, RTK, TrkB or other
therapeutic
targets to be materially different from any future results,
performance or
achievements expressed or implied by such statements. There can be no
guarantee
that allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7,
GABA-BR,
FSHR/LHR, GLP1R, TNFR1, RTK, TrkB or other therapeutics targets
will be
approved for sale in any market or by any regulatory authority. Nor can
there be
any guarantee that allosteric modulators of mGluR2, mGluR4, mGluR5,
mGluR7,
GABA-BR, FSHR/LHR, GLP1R, TNFR1, RTK, TrkB or other therapeutic targets
will
achieve any particular levels of revenue (if any) in the future. In
particular,
management's expectations regarding allosteric modulators of mGluR2,
mGluR4,
mGluR5, mGluR7, GABA-BR, FSHR/LHR, GLP1R, TNFR1, RTK, TrkB or other
therapeutic
targets could be affected by, among other things, unexpected actions
by our
partners, unexpected regulatory actions or delays or government
regulation
generally; unexpected clinical trial results, including unexpected new
clinical
data and unexpected additional analysis of existing clinical data;
competition
in general; government, industry and general public pricing
pressures; the
company's ability to obtain or maintain patent or other proprietary
intellectual
property protection. Should one or more of these risks or
uncertainties
materialize, or should underlying assumptions prove incorrect, actual
results
may vary materially from those anticipated, believed, estimated or
expected.
Addex Pharmaceuticals Ltd is providing the information in this press
release as
of this date and does not undertake any obligation to update any
forward-looking
statements contained in this press release as a result of new
information,
future events or otherwise, except as may be required by applicable laws.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Addex Pharmaceuticals via Thomson Reuters ONE
[HUG#1584450]
Chris Maggos
Business Development & Communication
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos(at)addexpharma.com
GENEVA -- (Marketwire) -- 02/10/12 --
Addex Pharmaceuticals (SWISS: ADXN), a
leading biopharmaceutical company pioneering allosteric modulation-based
drug
discovery and development, announced today that Dr. Bharatt Chowrira,
CEO of
Addex, will present at 9am EST on February 14, 2012, at the BIO CEO &
Investor
Conference in New York City. Dr. Chowrira will highlight the Company's
oral
small molecule drug discovery and development platform and provide a
review of
its pipeline,
|
|
Parkinson's
disease and schizophrenia. The presentation, live webcast and webcast
replay
will be available via the Internet at:
www.veracast.com/webcasts/bio/ceoinvestor2012/08 .. : www.veracast.com/webcasts/bio/ceoinvestor2012/08 ..
Addex Pharmaceuticals ( www.addexpharma.com : www.addexpharma.com ) discovers and develops an
emerging
class of small molecule drugs, called allosteric modulators, which
have the
potential to be more specific and confer significant therapeutic advantages
over
conventional "orthosteric" small molecule or biological drugs. The Company
uses
its proprietary discovery platform to address receptors and other proteins
that
are recognized as attractive targets for modulation of important diseases
with
unmet medical needs. The Company's two lead products are being
investigated in
Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5
negative
allosteric modulator or NAM) is being developed by Addex to treat
Parkinson's
disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2
positive
allosteric modulator or PAM) is being developed by our partner
Janssen
Pharmaceuticals Inc. to treat schizophrenia. Addex also is advancing
several
preclinical programs including: GABA-BR PAM for pain, overactive
bladder and
other disorders; mGluR4 PAM for Parkinson's, anxiety and other diseases;
GLP1R
PAM for type 2 diabetes; mGluR2 NAM for treating Alzheimer's
disease and
depression; and FSHR/LHR NAM for sex hormone dependent tumors &
reproductive
system disorders. In addition, Addex has discovery programs to
identify
allosteric modulators of: receptor tyrosine kinase (RTK) superfamily,
including
TrkB PAM for treating neurodegenerative diseases (e.g. Alzheimer's,
Parkinson's
and Huntington's diseases); and TNF receptor superfamily, including
TNFR1 NAM
for inflammation (e.g. rheumatoid arthritis) and other diseases.
Disclaimer: The foregoing release may contain forward-looking statements
that
can be identified by terminology such as "not approvable",
"continue",
"believes", "believe", "will", "remained open to exploring", "would",
"could",
or similar expressions, or by express or implied discussions regarding
Addex
Pharmaceuticals Ltd, its business, the potential approval of its
products by
regulatory authorities, or regarding potential future revenues from
such
products. Such forward-looking statements reflect the current views of
Addex
Pharmaceuticals Ltd regarding future events, future economic
performance or
prospects, and, by their very nature, involve inherent risks and
uncertainties,
both general and specific, whether known or unknown, and/or any other
factor
that may materially differ from the plans, objectives, expectations,
estimates
and intentions expressed or implied in such forward-looking statements.
Such may
in particular cause actual results with allosteric modulators of mGluR2,
mGluR4,
mGluR5, mGluR7, GABA-BR, FSHR/LHR, GLP1R, TNFR1, RTK, TrkB or other
therapeutic
targets to be materially different from any future results,
performance or
achievements expressed or implied by such statements. There can be no
guarantee
that allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7,
GABA-BR,
FSHR/LHR, GLP1R, TNFR1, RTK, TrkB or other therapeutics targets
will be
approved for sale in any market or by any regulatory authority. Nor can
there be
any guarantee that allosteric modulators of mGluR2, mGluR4, mGluR5,
mGluR7,
GABA-BR, FSHR/LHR, GLP1R, TNFR1, RTK, TrkB or other therapeutic targets
will
achieve any particular levels of revenue (if any) in the future. In
particular,
management's expectations regarding allosteric modulators of mGluR2,
mGluR4,
mGluR5, mGluR7, GABA-BR, FSHR/LHR, GLP1R, TNFR1, RTK, TrkB or other
therapeutic
targets could be affected by, among other things, unexpected actions
by our
partners, unexpected regulatory actions or delays or government
regulation
generally; unexpected clinical trial results, including unexpected new
clinical
data and unexpected additional analysis of existing clinical data;
competition
in general; government, industry and general public pricing
pressures; the
company's ability to obtain or maintain patent or other proprietary
intellectual
property protection. Should one or more of these risks or
uncertainties
materialize, or should underlying assumptions prove incorrect, actual
results
may vary materially from those anticipated, believed, estimated or
expected.
Addex Pharmaceuticals Ltd is providing the information in this press
release as
of this date and does not undertake any obligation to update any
forward-looking
statements contained in this press release as a result of new
information,
future events or otherwise, except as may be required by applicable laws.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Addex Pharmaceuticals via Thomson Reuters ONE
[HUG#1584450]
Chris Maggos
Business Development & Communication
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos(at)addexpharma.com
